Japan has cautiously eased regulatory requirements related to novel drugs for rare diseases, with the Ministry of Health, Labour and Welfare (MHLW) to allow approval filings without data from Japanese clinical trials under certain conditions.
At the same time, the ministry has also expanded flexibilities around a related conditional approval scheme